TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients

被引:63
|
作者
Halvorsen, Ann R. [1 ]
Silwal-Pandit, Laxmi [1 ]
Meza-Zepeda, Leonardo A. [2 ,3 ]
Vodak, Daniel [2 ]
Phuong Vu [1 ]
Sagerup, Camilla [1 ]
Hovig, Eivind [2 ,4 ,5 ]
Myklebost, Ola [2 ]
Borresen-Dale, Anne-Lise [1 ,6 ]
Brustugun, Odd T. [1 ,7 ]
Helland, Aslaug [1 ,7 ]
机构
[1] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[2] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, N-0450 Oslo, Norway
[3] Oslo Univ Hosp, Inst Canc Res, Dept Core Facil, Genom Core Facil, N-0450 Oslo, Norway
[4] Univ Oslo, Dept Informat, Oslo, Norway
[5] Oslo Univ Hosp, Inst Canc Genet & Informat, N-0450 Oslo, Norway
[6] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway
[7] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway
来源
FRONTIERS IN GENETICS | 2016年 / 7卷
关键词
P53; MUTATIONS; SOMATIC MUTATIONS; SURVIVAL; GENE;
D O I
10.3389/fgene.2016.00085
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: TP53 mutations are among the most common mutations found in lung cancers, identified as an independent prognostic factor in many types of cancers. The purpose of this study was to investigate the frequency and prognostic impact of TP53 mutations in never-smokers and in different histological subtypes of lung cancer. Methods: We analyzed tumor tissue from 394 non-small cell carcinomas including adenocarcinomas (n = 229), squamous cell carcinomas (n = 112), large cell carcinomas (n = 30), and others (n = 23) for mutations in TP53 by the use of Sanger sequencing (n = 394) and next generation sequencing (n = 100). Results: TP53 mutations were identified in 47.2% of the samples, with the highest frequency (65%) of mutations among squamous cell carcinomas. Among never smokers, 36% carried a TP53 mutation, identified as a significant independent negative prognostic factor in this subgroup. For large cell carcinomas, a significantly prolonged progression free survival was found for those carrying a TP53 mutation. In addition, the frequency of frameshift mutations was doubled in squamous cell carcinomas (20.3%) compared to adenocarcinomas (9.1 %). Conclusion: TP53 mutation patterns differ between the histological subgroups of lung cancers, and are also influenced by smoking history. This indicates that the histological subtypes in lung cancer are genetically different, and that smoking-induced TP53 mutations may have a different biological impact than TP53 mutations occurring in never-smokers.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] TP53 mutation spectrum in lung cancer is not different in women and men
    Marrogi, AJ
    Mechanic, LE
    Welsh, JA
    Bowman, ED
    Khan, MA
    Enewold, L
    Shields, PG
    Harris, CC
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (04) : 1031 - 1033
  • [2] Polymorphisms in XPD and TP53 and mutation in human lung cancer
    Mechanic, LE
    Marrogi, AJ
    Welsh, JA
    Bowman, ED
    Khan, MA
    Enewold, L
    Zheng, YL
    Chanock, S
    Shields, PG
    Harris, CC
    CARCINOGENESIS, 2005, 26 (03) : 597 - 604
  • [3] Smoking, lung cancers and their TP53 mutations
    Cooper, CS
    MUTAGENESIS, 2002, 17 (04) : 279 - 280
  • [4] TP53 mutation, mitochondria and cancer
    Kamp, William M.
    Wang, Ping-yuan
    Hwang, Paul M.
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2016, 38 : 16 - 22
  • [5] TP53 mutation in colorectal cancer
    Iacopetta, B
    HUMAN MUTATION, 2003, 21 (03) : 271 - 276
  • [6] TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke:: lessons from the IARC TP53 mutation database
    Hainaut, P
    Olivier, M
    Pfeifer, GP
    MUTAGENESIS, 2001, 16 (06) : 551 - 553
  • [7] TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke:: Distinct patterns in never, former, and current smokers
    Le Calvez, F
    Mukeria, A
    Hunt, JD
    Kelm, O
    Hung, RJ
    Tanière, P
    Brennan, P
    Boffetta, P
    Zaridze, DG
    Hainaut, P
    CANCER RESEARCH, 2005, 65 (12) : 5076 - 5083
  • [8] The spectrum of TP53 mutations in Rwandan patients with gastric cancer
    Augustin Nzitakera
    Jean Bosco Surwumwe
    Ella Larissa Ndoricyimpaye
    Schifra Uwamungu
    Delphine Uwamariya
    Felix Manirakiza
    Marie Claire Ndayisaba
    Gervais Ntakirutimana
    Benoit Seminega
    Vincent Dusabejambo
    Eric Rutaganda
    Placide Kamali
    François Ngabonziza
    Rei Ishikawa
    Belson Rugwizangoga
    Yuji Iwashita
    Hidetaka Yamada
    Kimio Yoshimura
    Haruhiko Sugimura
    Kazuya Shinmura
    Genes and Environment, 46
  • [9] The spectrum of TP53 mutations in Rwandan patients with gastric cancer
    Nzitakera, Augustin
    Surwumwe, Jean Bosco
    Ndoricyimpaye, Ella Larissa
    Uwamungu, Schifra
    Uwamariya, Delphine
    Manirakiza, Felix
    Ndayisaba, Marie Claire
    Ntakirutimana, Gervais
    Seminega, Benoit
    Dusabejambo, Vincent
    Rutaganda, Eric
    Kamali, Placide
    Ngabonziza, Francois
    Ishikawa, Rei
    Rugwizangonga, Belson
    Iwashita, Yuji
    Yamada, Hidetaka
    Yoshimura, Kimio
    Sugimura, Haruhiko
    Shinmura, Kazuya
    GENES AND ENVIRONMENT, 2024, 46 (01)
  • [10] The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
    Aisner, Dara L.
    Sholl, Lynette M.
    Berry, Lynne D.
    Rossi, Michael R.
    Chen, Heidi
    Fujimoto, Junya
    Moreira, Andre L.
    Ramalingam, Suresh S.
    Villaruz, Liza C.
    Otterson, Gregory A.
    Haura, Eric
    Politi, Katerina
    Glisson, Bonnie
    Cetnar, Jeremy
    Garon, Edward B.
    Schiller, Joan
    Waqar, Saiama N.
    Sequist, Lecia V.
    Brahmer, Julie
    Shyr, Yu
    Kugler, Kelly
    Wistuba, Ignacio I.
    Johnson, Bruce E.
    Minna, John D.
    Kris, Mark G.
    Bunn, Paul A.
    Kwiatkowski, David J.
    CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1038 - 1047